Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
The overall goal of this study is to evaluate the effect of a testosterone drug called
Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue,
sexual function, quality of life, body composition, muscle strength, and physical activity in
young cancer survivors who report fatigue and have low testosterone. Main hypothesis is that
Testosterone administration in young male cancer survivors who are in remission for at least
1 year, report cancer-related fatigue and have symptomatic testosterone deficiency will be
associated with greater improvements in fatigue scores compared with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Seattle Institute for Biomedical and Clinical Research